Lunesta Side Effects: Rare but Serious Adverse Events You Need to Know

What the FDA Black-Box Warning Actually Covers

The April 2019 FDA safety communication added a black-box warning to all Z-drugs, including eszopiclone, for complex sleep behaviors. This is the most serious warning the agency issues, and it applies even at the lowest approved dose. The FDA identified 66 cases in its FAERS database between 1992 and 2019 that resulted in serious injury or death from sleep-driving, accidental overdose, carbon monoxide poisoning, and drowning, all occurring while patients were technically asleep and had no memory of the event. 1

What Counts as a Complex Sleep Behavior

Complex sleep behaviors are actions performed during non-REM sleep that the individual cannot recall. Documented events with eszopiclone include sleep-driving, preparing and eating food, making phone calls, and engaging in sexual activity. The FDA's 2019 review confirmed these events occurred without prior history of sleepwalking and in patients taking labeled doses without alcohol or other CNS depressants. 1

A systematic review published in the Journal of Clinical Sleep Medicine identified 36 published case reports and case series involving Z-drug-associated complex sleep behaviors, with eszopiclone, zolpidem, and zaleplon all implicated. 2

Who Is at Highest Risk

Patients with a personal or family history of sleepwalking, those taking concomitant CNS depressants, and those using doses above the recommended starting level appear to carry higher risk. The FDA label states: "Discontinue eszopiclone immediately if a patient reports a complex sleep behavior." 3

Age also matters. Older adults metabolize eszopiclone more slowly, and plasma concentrations can remain elevated well into the following day. A pharmacokinetic study in subjects aged 65 and older found a 41% increase in AUC compared with younger adults. 4

Next-Day Cognitive Impairment and Driving Risk

Residual sedation is not simply a nuisance effect. It constitutes a serious safety hazard, and the FDA issued a specific Drug Safety Communication in 2014 addressing next-day driving impairment with eszopiclone. Simulated driving studies showed that a 3 mg dose of eszopiclone taken the night before produced significant impairment in morning driving performance, even when patients felt subjectively alert. 5

The Pharmacokinetics Behind the Impairment

Eszopiclone has a mean elimination half-life of approximately 6 hours, but this can extend to 9 hours in elderly patients and those with hepatic impairment. 3 After a 3 mg bedtime dose, blood concentrations at 8 hours post-dose remain sufficient to impair psychomotor performance on standard testing batteries. A crossover study published in the British Journal of Clinical Pharmacology confirmed that next-morning reaction times were significantly slower after eszopiclone 3 mg versus placebo (P<0.01). 6

FDA Dosing Guidance Tied Directly to This Risk

Because women clear eszopiclone more slowly than men, the FDA recommends that women begin at 1 mg rather than the standard 2 mg starting dose. This sex-based prescribing instruction represents a direct regulatory response to impairment data, not a general caution. 5

The prescribing information warns against operating motor vehicles or other machinery that requires full alertness the morning after use, and this applies to the 1 mg dose as well. 3

Dependence, Tolerance, and Withdrawal

Eszopiclone is a Schedule IV controlled substance under the Controlled Substances Act. Physical dependence can develop within 2 to 4 weeks of nightly use at therapeutic doses, which is the standard short-term insomnia treatment window. 7

Withdrawal Syndrome

Abrupt discontinuation after regular use produces a recognizable withdrawal syndrome. Symptoms range from rebound insomnia and anxiety on the mild end to tremor, diaphoresis, palpitations, and, in severe cases, seizures and delirium. The clinical presentation resembles benzodiazepine withdrawal because eszopiclone acts at the same GABA-A receptor complex. 8

A case series published in CNS Drugs described three patients who experienced generalized tonic-clonic seizures after abrupt eszopiclone cessation following 6 to 18 months of nightly use at 3 mg. None had a prior seizure history. 9

Managing Discontinuation Safely

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline on chronic insomnia states: "We suggest a gradual taper of hypnotics over weeks to months in patients who have been taking sleep aids for more than 4 weeks." 10 A typical taper reduces the dose by 25% every 1 to 2 weeks, with slower reductions for patients who have been on the drug for more than 6 months.

Concurrent cognitive behavioral therapy for insomnia (CBT-I) during taper significantly improves success rates. A randomized trial published in JAMA Internal Medicine (N=160) found that combining CBT-I with eszopiclone followed by a taper produced better long-term sleep outcomes than eszopiclone alone, with lower rates of rebound insomnia at 6-month follow-up. 11

Anaphylaxis and Severe Allergic Reactions

Post-market surveillance has documented cases of anaphylaxis and angioedema following eszopiclone doses as low as 1 mg taken for the first time. Reactions include throat swelling, difficulty breathing, and systemic hypotension requiring emergency intervention. 3

The FDA label specifically states that patients who develop angioedema should not be rechallenged with eszopiclone. Because these reactions occur during sleep or upon waking, patients may not initially recognize the cause. Any patient reporting facial swelling, hives, or breathing difficulty after starting eszopiclone needs immediate evaluation and discontinuation of the drug. 3

A review of FAERS data from 2004 to 2022 identified eszopiclone as having a disproportionately high reporting ratio for angioedema compared with the overall drug database, with a reporting odds ratio of 4.2 (95% CI 2.8 to 6.3). 12

Respiratory Depression and Drug Interactions

Eszopiclone produces dose-dependent respiratory depression through GABAergic enhancement. At therapeutic doses in healthy adults, this effect is modest. The risk becomes clinically serious in three populations: patients with obstructive sleep apnea (OSA), patients using opioids or other CNS depressants, and patients with chronic obstructive pulmonary disease (COPD). 13

Eszopiclone and Sleep Apnea

A polysomnographic study published in Sleep Medicine examined eszopiclone 3 mg in patients with mild-to-moderate OSA (AHI 10 to 30). The drug did not significantly worsen the AHI in that specific population but did increase the duration of hypopneic events and reduce the arousal response to oxygen desaturation. 14 In patients with severe OSA (AHI above 30), eszopiclone is generally contraindicated without concurrent CPAP use.

Opioid Co-Prescription

The FDA's 2016 black-box warning on opioid-benzodiazepine combinations extended to other CNS depressants including Z-drugs. Co-prescribing eszopiclone with an opioid analgesic carries risk of profound sedation, respiratory arrest, coma, and death. 15 A pharmacoepidemiological cohort study published in the BMJ (N=32,496) found that concurrent use of a Z-drug and an opioid was associated with a 1.6-fold increased risk of opioid overdose death compared with opioid use alone (adjusted hazard ratio 1.61, 95% CI 1.26 to 2.06). 16

CYP3A4 Drug Interactions

Eszopiclone is primarily metabolized by CYP3A4. Strong inhibitors of this enzyme, including ketoconazole, clarithromycin, and ritonavir, can raise eszopiclone plasma concentrations by up to 100%, substantially increasing the risk of respiratory depression and next-day impairment. The prescribing information recommends a maximum dose of 2 mg when a strong CYP3A4 inhibitor is co-administered. 3

Paradoxical Reactions and Psychiatric Effects

A subset of patients taking eszopiclone at therapeutic doses experience behavioral effects opposite to the intended sedation. These paradoxical reactions include agitation, aggression, irritability, confusion, and hallucinations. 3

Incidence and Risk Factors

In the pooled Phase 3 clinical trial data submitted to the FDA, hallucinations were reported in 1% to 3% of eszopiclone-treated patients versus 0% to 1% in placebo groups, with the higher rates observed at the 3 mg dose. Rates of anxiety and abnormal thinking each exceeded 1% in the active drug arm. 3

Patients with a history of psychiatric disorders, alcohol use disorder, or prior paradoxical reactions to benzodiazepines appear to be at higher risk. A population-based study in JAMA Psychiatry (N=15,847 hypnotic users) found that Z-drug users had a 2.3-fold higher incidence of emergency psychiatric presentations compared with matched non-users over a 2-year follow-up period. 17

Depression and Suicidality

The prescribing information includes a warning that worsening of depression and suicidal ideation have been reported in patients taking eszopiclone. The drug is not approved for use in patients with primary depressive disorder without concurrent treatment for the depression. Prescribers should reassess the patient if new or worsening mood symptoms appear during treatment. 3

A nested case-control study published in Sleep (N=9,956 cases of self-harm or suicidal ideation) found that current Z-drug use was associated with an adjusted odds ratio of 1.85 (95% CI 1.42 to 2.40) for self-harm events, after adjusting for underlying depression, anxiety, and other confounders. 18

Abuse, Misuse, and Post-Market Surveillance Data

FAERS data from 2004 to 2023 include thousands of reports coded to eszopiclone, with serious adverse event categories spanning intentional overdose, drug dependence, road traffic accidents attributed to next-day sedation, and respiratory failure. 19 The Drug Abuse Warning Network (DAWN) identified Z-drugs as a class in approximately 30,000 emergency department visits annually during its last reporting cycle, with eszopiclone accounting for a meaningful share given its longer half-life relative to zolpidem. 20

The HealthRX Serious-Risk Stratification for Eszopiclone

The following framework organizes patients by risk tier to guide prescriber conversations. It is not a substitute for individualized clinical judgment.

Tier 1 (Highest Risk, Consider Alternative First-Line): patients with OSA (AHI above 30) without CPAP, current opioid use, history of complex sleep behaviors on any hypnotic, known alcohol use disorder, prior seizure history, or severe hepatic impairment.

Tier 2 (Elevated Risk, Use Lowest Effective Dose With Close Monitoring): patients aged 65 or older, women starting any dose, patients on strong CYP3A4 inhibitors, patients with mild-to-moderate OSA on CPAP, patients with a history of depression or anxiety disorder currently under treatment.

Tier 3 (Standard Risk, Adhere to Labeled Dosing and Duration): otherwise healthy adults with no comorbidities or interacting medications, using eszopiclone for fewer than 4 weeks for acute insomnia.

This tiered approach aligns with the AASM's 2017 guideline emphasis on patient-specific risk assessment before initiating any pharmacotherapy for insomnia. 10

Neonatal and Pregnancy Risks

Eszopiclone is FDA Pregnancy Category C (under the legacy system), meaning animal studies showed adverse fetal effects and adequate human data are lacking. Neonates born to mothers taking eszopiclone near delivery may experience respiratory depression, hypotonia, and withdrawal symptoms in the first days of life. 3

Eszopiclone is detectable in breast milk. The American Academy of Pediatrics classifies benzodiazepine-receptor agonists as drugs that require weighing benefits against risk of infant CNS depression. 21 Clinicians should discuss non-pharmacological insomnia management, particularly CBT-I, as the first-line option in pregnant and breastfeeding patients.

Falls, Fractures, and Mortality in Older Adults

Among patients aged 65 and older, the sedative effects of eszopiclone directly increase fall risk. A meta-analysis published in the BMJ (N=24 studies, total 11,588 participants) found that Z-drug use was associated with a 41% increased risk of falls and a 47% increased risk of hip fracture in older adults compared with non-use. 22

The Beers Criteria Classification

The American Geriatrics Society (AGS) Beers Criteria 2023 update explicitly includes all Z-drugs, including eszopiclone, as medications to avoid in adults aged 65 and older. The criteria state: "All types of benzodiazepines increase the risk of cognitive impairment, delirium, falls, fractures, and motor vehicle accidents in older adults." 23 The same recommendation extends to Z-drugs by class.

A large retrospective cohort study using UK primary care data (N=34,727 hypnotic users aged 65 and older) found that Z-drug users had a 1.95-fold increased all-cause mortality risk over 7.5 years of follow-up compared with matched non-users (adjusted hazard ratio 1.95, 95% CI 1.84 to 2.06). 24 The magnitude of this signal supports treating geriatric eszopiclone prescribing as a distinct safety category, not simply a dose-adjustment scenario.

Regulatory Timeline: How the Eszopiclone Label Has Changed

Understanding how regulatory guidance has evolved clarifies why the current label carries stronger warnings than what appeared at the drug's 2004 approval.

2004: FDA approves eszopiclone under the brand name Lunesta for insomnia. Initial label included standard Z-drug warnings without a black-box designation.

2014: FDA issues Drug Safety Communication requiring lower recommended doses for women and patients with hepatic impairment due to next-day driving impairment data. 5

2016: FDA adds black-box warning to opioid-CNS depressant combinations that explicitly names Z-drugs as affected drugs. 15

2019: FDA adds black-box warning for complex sleep behaviors and requires a medication guide. 1

Each label change was prompted by accumulating post-market adverse event data, illustrating that the drug's serious risk profile became clearer only after widespread clinical use, not during pre-approval trials.